| Epidermal growth factor protects epithelial cells against Fas-induced apoptosis: requirement for Akt activation S Gibson, S Tu, R Oyer, SM Anderson, GL Johnson Journal of Biological Chemistry 274 (25), 17612-17618, 1999 | 318 | 1999 |
| Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation WJ Wu, S Tu, RA Cerione Cell 114 (6), 715-725, 2003 | 240 | 2003 |
| In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis S Tu, GP McStay, LM Boucher, T Mak, HM Beere, DR Green Nature cell biology 8 (1), 72-77, 2006 | 230 | 2006 |
| The multidomain proapoptotic molecules Bax and Bak are directly activated by heat LJ Pagliari, T Kuwana, C Bonzon, DD Newmeyer, S Tu, HM Beere, ... Proceedings of the National Academy of Sciences 102 (50), 17975-17980, 2005 | 229 | 2005 |
| Epidermal growth factor-dependent regulation of Cdc42 is mediated by the Src tyrosine kinase S Tu, WJ Wu, J Wang, RA Cerione Journal of Biological Chemistry 278 (49), 49293-49300, 2003 | 143 | 2003 |
| Cdc42 is a substrate for caspases and influences Fas-induced apoptosis S Tu, RA Cerione Journal of Biological Chemistry 276 (22), 19656-19663, 2001 | 100 | 2001 |
| Luck/unluck of the draw: an empirical study of examiner allowance rates S Tu Stan. Tech. L. Rev., 10, 2012 | 54 | 2012 |
| Antiapoptotic Cdc42 mutants are potent activators of cellular transformation SS Tu, WJ Wu, W Yang, P Nolbant, K Hahn, RA Cerione Biochemistry 41 (41), 12350-12358, 2002 | 32 | 2002 |
| What litigators can teach the Patent Office about pharmaceutical patents SS Tu, MA Lemley Wash. UL Rev. 99, 1673, 2021 | 30 | 2021 |
| Invalidated Patents and Associated Patent Examiners S Tu Vand. J. Ent. & Tech. L. 18, 135, 2015 | 26 | 2015 |
| Patent examiners and litigation outcomes S Tu Stan. Tech. L. Rev. 17, 507, 2013 | 21 | 2013 |
| Patenting Fast and Slow: Examiner and Applicant Use of Prior Art SS Tu Cardozo Arts & Ent. LJ 38, 391, 2020 | 15 | 2020 |
| Three new metrics for patent examiner activity: Office actions per grant ratio (OGR), office actions per disposal ratio (ODR), and grant to examiner ratio (GER) SS Tu J. Pat. & Trademark Off. Soc'y 100, 277, 2018 | 15 | 2018 |
| Patenting Fast and Slow: Examiner Rejections and Applicant Traversals to Nonprior Art Rejections SS Tu Mich. St. L. Rev., 411, 2021 | 10 | 2021 |
| Understanding the Backlog Problems Associated with Requests for Continued Examination Practice S Tu Duke L. & Tech. Rev. 13, 216, 2014 | 10 | 2014 |
| Patents and regulatory exclusivities on GLP-1 receptor agonists R Alhiary, AS Kesselheim, S Gabriele, RF Beall, SS Tu, WB Feldman JAMA 330 (7), 650-657, 2023 | 9 | 2023 |
| Free Speech in the Balance: Judicial Sanctions and Frivolous SLAPP Suits SS Tu, NF Stump Loy. LAL Rev. 54, 623, 2020 | 9 | 2020 |
| Five-year sales for newly marketed prescription drugs with and without initial orphan drug act designation SS Tu, S Nagar, AS Kesselheim, Z Lu, BN Rome JAMA 329 (18), 1607-1608, 2023 | 7 | 2023 |
| Antibody Patents: Use of the Written Description and Enablement Requirements at the Patent & Trademark Offices SS Tu, CM Holman Berkeley Tech. LJ 38, 1, 2023 | 7 | 2023 |
| Overqualified and Underrepresented: Gender Inequality in Pharmaceutical Patent Law SS Tu, PR Gugliuzza, A Semet BYU L. Rev. 48, 137, 2022 | 7 | 2022 |
Aaron KesselheimProfessor of Medicine, Harvard Medical School & Brigham and Women's HospitalVerified email at partners.org
